PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy

BACKGROUND. Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive netwo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI Insight
Hauptverfasser: Kalathil, Suresh Gopi, Lugade, Amit Anand, Miller, Austin, Iyer, Renuka, Thanavala, Yasmin
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2016
Schlagworte:
Clinical Medicine
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986927/
https://ncbi.nlm.nih.gov/pubmed/27540594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86182
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge